Venkatesh Sarampally,Soumyadeep Poddar,Pragya Trivedi,Abhilash Rana,Ajay K Singh,Kunta Chandra Shekar,Biswajit Saha,Avijit Jana
{"title":"“NO”意味着Yes:通过光响应顺序递送在三阴性乳腺癌3D球体平台中释放一氧化氮(NO)和氯苯(Cbl)的治疗协同作用,并具有转录组学见解。","authors":"Venkatesh Sarampally,Soumyadeep Poddar,Pragya Trivedi,Abhilash Rana,Ajay K Singh,Kunta Chandra Shekar,Biswajit Saha,Avijit Jana","doi":"10.1021/acs.jmedchem.5c01995","DOIUrl":null,"url":null,"abstract":"Nitric oxide (NO) is a multifunctional signaling molecule in oncology, influencing tumor progression, apoptosis, and immune responses. In contrast, chlorambucil (Cbl), a DNA-alkylating chemotherapeutic, induces cytotoxicity through DNA damage. Here, we report a photoresponsive nanoparticle platform for sequential codelivery of NO and Cbl, where NO is released within 10 min of irradiation, followed by Cbl release within 30 min. The nanoplatform employs a coumarin-4-ylmethyl photoremovable protecting group (PRPG) to achieve light-triggered spatiotemporal release of both agents. Using 2D cultures and 3D triple-negative breast cancer (TNBC) spheroids, we observed that NO-assisted chemotherapy markedly improved tumor inhibition and apoptosis compared to Cbl alone. Transcriptomic profiling (RNA-seq) revealed modulation of oncogenic pathways (PI3K/AKT, NF-κB, MAPK, EMT) with upregulation of tumor suppressors (TP53, CASP10, TIMP1) and downregulation of oncogenes (BCL2, MMP9, VEGFC). Additionally, suppression of IL-6, TNF-α, and ECM remodeling factors indicated reduced metastatic potential. This strategy highlights NO-mediated synergy as a promising approach to overcome chemoresistance in TNBC.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"45 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"\\\"NO\\\" Means Yes: Unlocking the Therapeutic Synergy of Nitric Oxide (NO) and Chlorambucil (Cbl) via Photoresponsive Sequential Delivery in a Triple-Negative Breast Cancer 3D Spheroidal Platform with Transcriptomic Insights.\",\"authors\":\"Venkatesh Sarampally,Soumyadeep Poddar,Pragya Trivedi,Abhilash Rana,Ajay K Singh,Kunta Chandra Shekar,Biswajit Saha,Avijit Jana\",\"doi\":\"10.1021/acs.jmedchem.5c01995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Nitric oxide (NO) is a multifunctional signaling molecule in oncology, influencing tumor progression, apoptosis, and immune responses. In contrast, chlorambucil (Cbl), a DNA-alkylating chemotherapeutic, induces cytotoxicity through DNA damage. Here, we report a photoresponsive nanoparticle platform for sequential codelivery of NO and Cbl, where NO is released within 10 min of irradiation, followed by Cbl release within 30 min. The nanoplatform employs a coumarin-4-ylmethyl photoremovable protecting group (PRPG) to achieve light-triggered spatiotemporal release of both agents. Using 2D cultures and 3D triple-negative breast cancer (TNBC) spheroids, we observed that NO-assisted chemotherapy markedly improved tumor inhibition and apoptosis compared to Cbl alone. Transcriptomic profiling (RNA-seq) revealed modulation of oncogenic pathways (PI3K/AKT, NF-κB, MAPK, EMT) with upregulation of tumor suppressors (TP53, CASP10, TIMP1) and downregulation of oncogenes (BCL2, MMP9, VEGFC). Additionally, suppression of IL-6, TNF-α, and ECM remodeling factors indicated reduced metastatic potential. This strategy highlights NO-mediated synergy as a promising approach to overcome chemoresistance in TNBC.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"45 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.5c01995\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c01995","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
"NO" Means Yes: Unlocking the Therapeutic Synergy of Nitric Oxide (NO) and Chlorambucil (Cbl) via Photoresponsive Sequential Delivery in a Triple-Negative Breast Cancer 3D Spheroidal Platform with Transcriptomic Insights.
Nitric oxide (NO) is a multifunctional signaling molecule in oncology, influencing tumor progression, apoptosis, and immune responses. In contrast, chlorambucil (Cbl), a DNA-alkylating chemotherapeutic, induces cytotoxicity through DNA damage. Here, we report a photoresponsive nanoparticle platform for sequential codelivery of NO and Cbl, where NO is released within 10 min of irradiation, followed by Cbl release within 30 min. The nanoplatform employs a coumarin-4-ylmethyl photoremovable protecting group (PRPG) to achieve light-triggered spatiotemporal release of both agents. Using 2D cultures and 3D triple-negative breast cancer (TNBC) spheroids, we observed that NO-assisted chemotherapy markedly improved tumor inhibition and apoptosis compared to Cbl alone. Transcriptomic profiling (RNA-seq) revealed modulation of oncogenic pathways (PI3K/AKT, NF-κB, MAPK, EMT) with upregulation of tumor suppressors (TP53, CASP10, TIMP1) and downregulation of oncogenes (BCL2, MMP9, VEGFC). Additionally, suppression of IL-6, TNF-α, and ECM remodeling factors indicated reduced metastatic potential. This strategy highlights NO-mediated synergy as a promising approach to overcome chemoresistance in TNBC.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.